{"slug":"selank-sciatica","verification":{"valid":true,"entries":2,"head":"2a15feb56f57cfdaaf429cc1365b75d6bfdb14d02c40337268e5bede86f49e31"},"count":2,"sources":[{"id":"s1","type":"pubmed","url":"https://www.sciencedirect.com/science/article/pii/S0924933812752811","title":"Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank","quote":"40% of patients were rapid responders (RR) ... 60% of patients responded gradually ... Clinically significant changes of mean HARS total score from 16.1[7.2] to 6.2[4.7] were achieved at Day 14","summary":"Small Russian trial on Selank in GAD showing variable response speed and anxiety score reductions.","claim_ids":["c1","c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:37:00.860Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"453ef805bac161bb61c7512c442a08d208136cf789b0eda6e8cdcd5af51a68a2"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves the Clinical Signs of Neuropathy","quote":"The results of these studies show that ARA 290 prevents tissue injury, reduces inflammation and activates healing. In preclinical models of neuropathy, ARA ...","summary":"Review and pilot data on ARA-290 for neuropathic conditions including sarcoidosis SFN.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:37:00.860Z","link_status":"ok","quote_status":"unverified","prev":"453ef805bac161bb61c7512c442a08d208136cf789b0eda6e8cdcd5af51a68a2","hash":"2a15feb56f57cfdaaf429cc1365b75d6bfdb14d02c40337268e5bede86f49e31"}]}